COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

FDA Reissues EUA for Convalescent Plasma to Permit the Use of Additional Antibody Test

convalescent plasma therapy as a COVID-19 treatment
Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on whatsapp
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

Convalescent plasma titers can now be qualified using the Mount Sinai COVID-19 ELISA IgG Antibody Test

The US Food and Drug Administration (FDA) announced Dec. 1, 2020, that it has reissued the emergency use authorization (EUA) for the use of convalescent plasma for treating COVID-19 in hospitalized patients. This EUA was initially issued in late August 2020, but it had the notable deficit of only permitting the use of a single SARS-CoV-2 antibody test for testing. (See Testing Donated Plasma: Clinical Laboratories Should Be Aware of Overlooked Requirement).

The initial EUA for convalescent plasma states that prior to use, units were required to be “tested by the Ortho VITROS SARS-CoV-2 IgG test and found to have a signal-to-cutoff (S/C) value of 12 or greater.” There were no other allowances made for testing potential units of convalescent plasma using other tests.

The December 2020 reissuance of the convalescent plasma EUA addressed this limitation by permitting a second SARS-CoV-2 antibody test to qualify potential plasma as containing the antibodies needed to treat COVID-19. The FDA announced, “The Letter of Authorization has been revised to add the Mount Sinai COVID-19 ELISA IgG Antibody Test as an acceptable test to be used for the purpose of qualifying high and low titer COVID-19 convalescent plasma in the manufacture of COVID-19 convalescent plasma.”

Related Resources:


Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at


Robert L. Michel
President, Founder
The Dark Intelligence Group